A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.

Authors

Shunsuke Kondo

National Cancer Center Hospital, Tokyo, Japan;

Shunsuke Kondo , Akihito Kawazoe , Satoru Iwasa , Noboru Yamamoto , Yuri Ueda , Satoshi Nagao , Takayuki Kimura , Ippei Suzuki , Nozomi Hayata , Toshiyuki Tamai , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

First Author: Brian Ko

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.

First Author: Andres Poveda

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.

First Author: Sarina Anne Piha-Paul

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.

First Author: Hui Kong Gan